TrueFi (TRU) sees 24-hour volatility of 209.2%: Trading volume surges over 8,700% and open interest spikes, raising risk of a short squeeze
Bitget Pulse2026/04/06 16:02Volatility Brief
In the past 24 hours, TRU price has surged from a low of $0.00434 to a high of $0.01342, currently quoted at $0.01026, with a massive amplitude of 209.2%. Trading volume skyrocketed to $177 million–$213 million, up over 8,724% from the previous day, with clear signs of net capital inflow.
Analysis of Abnormal Movements
- Both trading volume and Open Interest (OI) exploded: 24-hour trading volume soared by over 8,700%, with OI surging 78.31%, leading to a vertical price spike.
- Funding rate at -0.5813% alongside an RSI of 96 indicates signs of a short squeeze, directly amplifying the volatility.
No official announcements or notable on-chain whale transfers have been recorded within the past 24 hours.
Market Viewpoints and Outlook
Market sentiment is highly polarized. Traders see the asset as extremely overheated (RSI 96), anticipating ongoing high volatility and short squeeze risks while warning that aggressive structure may lead to corrections. Community mainstream calls for caution regarding liquidity traps, with no clear consensus on the market outlook.
Note: This analysis is auto-generated by AI based on public data and on-chain monitoring, for information purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Qualcomm (QCOM.US) Snapdragon Summit Preview: 2nm Dual-Chip Debuts, AI Diversification Narrative Faces Key Verification
Qualcomm is scheduled to hold its annual Snapdragon Summit in Maui, Hawaii, from September 22 to 24 local time.
SUI SuperTrend Flips to Buy — Macro Shift From Bearish to Bullish Begins

Novo Nordisk (NVO.US) unveils $23 billion pipeline blueprint, but the market isn't buying it! Investors ask, "How to turn the tide against adversity?"
After being surpassed by Eli Lilly in the obesity market, Novo Nordisk failed to present a concrete turnaround plan to CEO Mike Doustdal, disappointing investors. The company has pledged to launch more than five blockbuster drugs in the coming years and achieve over $23 billion in new sales, but the press conference lacked details on how to drive growth.

STONK hits new highs after erasing 27% crash
